{"classes":[{"categories":[{"measurements":[{"comment":"There are not enough events to calculate upper confidence bound.","groupId":"OG000","lowerLimit":"56","upperLimit":"NA","value":"215"},{"comment":"There are not enough events to calculate upper confidence bound.","groupId":"OG001","lowerLimit":"85","upperLimit":"NA","value":"106"},{"comment":"There are not enough events to calculate upper confidence bound.","groupId":"OG002","lowerLimit":"56","upperLimit":"NA","value":"102"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"description":"Progression-free survival time is the time from study entry to the documentation of disease progression or death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ibrutinib 560 mg on Days 1-28,\n\n* Lenalidomide 15 mg on Days 1-21 Dexamethasone 40 mg on Days 1,8,15, 22\n* Every 28 days","id":"OG000","title":"Dose Level 1 Starting Cohort"},{"description":"Ibrutinib 560 mg on Days 1-28,\n\n* Lenalidomide 25 mg on Days 1-21 Dexamethasone 40 mg on Days 1,8,15, 22\n* Every 28 days","id":"OG001","title":"Dose Level 2"},{"description":"Ibrutinib 840 mg on Days 1-28,\n\n* Lenalidomide 25 mg on Days 1-21 Dexamethasone 40 mg on Days 1,8,15, 22\n* Every 28 days","id":"OG002","title":"Dose Level 3"}],"paramType":"MEDIAN","populationDescription":"Per-protocol - all eligible patients who initiated protocol treatment regardless of DL received","reportingStatus":"POSTED","timeFrame":"34 Months","title":"Progression Free Survival","type":"SECONDARY","unitOfMeasure":"days"}